GlassScriptPhysician profile
Brigid K Ellis
NPI 1992932339
$3,527.26
in general payments reported to CMS, 2019-2025
24 companies · $843 in 2025
The $843 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $33.13 · 2021: $223 · 2022: $517 · 2023: $838 · 2024: $805 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $456.24 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $433.47 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $367.99 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $287.73 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $281.39 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.47 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $235.49 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $225.79 | 2023-2025 | Terlivaz |
| Fresenius USA Marketing, INC. | $188.90 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Daiichi Sankyo INC. | $135.01 | 2022-2025 | Injectafer |
| Scpharmaceuticals INC. | $128.26 | 2025 | |
| Glaxosmithkline, LLC. | $99.20 | 2023 | Benlysta |
| Lilly USA, LLC | $62.55 | 2023-2025 | Jardiance, Zepbound |
| Novo Nordisk INC | $61.58 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Shield Therapeutics INC | $52.11 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $44.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $42.05 | 2024-2025 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $31.63 | 2025 | Empaveli |
| Ardelyx, INC. | $28.81 | 2023 | Ibsrela |
| Genzyme Corporation | $19.68 | 2023 | |
| Horizon Therapeutics Plc | $19.66 | 2022 | |
| Chiesi USA, INC. | $18.24 | 2023 | Elfabrio |
| Novartis Pharmaceuticals Corporation | $16.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brigid Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.